EVALUATION OF THE DYNAMICS OF MENOPAUSAL UROGENITAL SYMPTOMS IN WOMEN AFTER SURGICAL CORRECTION OF URINARY INCONTINENCE OR GENITAL PROLAPSE DURING THERAPY WITH COMBINATION DRUG CONTAINING ESTROGEN, PROGESTERONE AND LACTOBACILLI


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The study included 125 peri- and postmenopausal women planning for surgical correction of urinary incontinence/pelvic organ prolapse with laboratory-confirmed clinical atrophic vulvovaginitis. All patients underwent surgery. Of these, 95 patients were treated with a combined drug containing estrogen, progesterone and lactobacilli at two stages: during 30 days prior to surgery (2 capsules a day for 20 days and 1 capsule a day for 10 days) and 30 days after the surgery (2 capsules per week). The control group consisted of 30 patients. At all stages of the treatment, subjective and objective assessment of the severity of urinary disorders and urogenital atrophy (UDI-6 questionnaire), assessment of their impact on the quality of life of patients (IIQ-7 questionnaire), evaluation of bacteriuria and vaginal biocenosis, the frequency of adverse events and postoperative complications were carried out. Patient’s baseline characteristics in studied groups were comparable. Both at the stage of preoperative preparation and in postoperative period, group of patients who received therapy showed a significant improvement in the clinical manifestations of urinary disorders (74 vs 100% at the end of the 1st stage of therapy, 28 vs 39% at the end of the 2nd stage of therapy, p<0.05), quality of life (70±7.7 vs 88±5.6 and 29±4.4 vs 38±2.9; p<0.05), symptoms of urogenital atrophy (43% vs 100 and 35 vs 71%; p<0.05) and indicators of the vaginal biocenosis (normocenosis - 88% vs 48 and 95 vs 62%; p<0.05). In addition, there was a trend towards decrease in the severity of bacteriuria in the group receiving treatment (64% vs 79 and 39 vs 45%; p<0.05). However, there were no significant differences in terms of the recovery of urination after surgery and length of hospital stay, as well as in the number of postoperative complications. Thus, application of a drug containing estrogen, progesterone and lactobacilli improves urogenital menopausal symptoms in women planning for the surgical correction of urinary incontinence and genital prolapse and it can be recommended in the pre- and postoperative periods.

Texto integral

Acesso é fechado

Sobre autores

D. Pushkar

SBEIHPE MSMSU n.a. A.I. Evdokimov of RMH

Department of Urology

M. Gvozdev

SBEIHPE MSMSU n.a. A.I. Evdokimov of RMH

Email: dr-gvozdev@mail.ru
MD, Associate Professor at the Department of Urology

N. Tupikina

SBEIHPE MSMSU n.a. A.I. Evdokimov of RMH

Department of Urology

Bibliografia

  1. Barlow D.H., Samsioe G., van Geelen J.H. A study of European women's experience of the problems of urogenital ageing and its management. Maturitas. 1997; 27: 239-47.
  2. Legendre G., Ringa V., Fauconnier A., Fritel X. Menopause, hormone treatment and urinary incontinence at midlife. Maturitas. 2013; 74: 26-30.
  3. Cardozo L., Bachmann G., McClish D., Fonda D., Birgenson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the hormones and urogenital therapy committee. Obstet. Gynecol. 1998; 92: 722-27.
  4. Iosif C.S., Bekassy Z. Prevalence of genito-urinary symptoms in the late menopause. Acta Obstet. Gynecol. Scand. 1984; 63: 257-60.
  5. Iosif C.S., Batra S., Ek A., Astedt B. Estrogen receptors in the human female lower urinary tract. Am. J. Obstet. Gynecol. 1981; 141: 817-20.
  6. Sturdee D.W., Panay N. Recommendations for the management of postmenopausal vaginal atrophy Climacteric. 2010; 13(6): 509-22.
  7. Raz R. Urinary tract infection in postmenopausal women. Korean J. Urol. 2011; 52: 801-8.
  8. Adriaens E., Remon J.P Mucosal irritation potential of personal lubricants relates to product osmolality as detected by the slug mucosal irritation assay. Sex. Transm. Dis. 2008; 35(5): 512-16.
  9. Griesser H., Skonietzki S., Fischer T., Fielder K., Suesskind M. Low dose estriol pessaries for the treatment of vaginal atrophy: A doubleblind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol. Maturitas. 2012; 71: 360-68.
  10. Dessole S., Rubattu G., Ambrosini G., Gallo O., Capobianco G., Cherchi P.L., Marci R., Cosmi E. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause. 2004; 11: 49-56.
  11. Stapleton A.E., Au-Yeung M., Hooton T.M., Fredricks D.N., Roberts P.L., Czaja C.A., Yarova-Yarovaia Y., Fiedler T., Cox M., Stamm W.E. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin. Infect. Dis. 2011; 52: 1212-17.
  12. Ozkinay E., Terek M.C., Yayci M., Kaiser R., Grob P., Tuncay G. The effectiveness of live lactobacilli in combination with low dose oestriol (Gynofl or) to restore the vaginal fl ora after treatment of vaginal infections. BJOG. 2005; 112: 234-40.
  13. Esposito G. Estriol: a weak estrogen or a different hormone? Gynecol. Endocrinol. 1991; 5: 131-53.
  14. Ballagh S.A. Vaginal hormone therapy for urogenital and menopausal symptoms. Semin. Reprod. Med. 2005; 23(2): 126-40.
  15. Paterson M.E., Wade-Evans T., Sturdee D.W., Thom M.H., Studd J.W. Endometrial disease after treatment with oestrogens and progestogens in the climacteric. BMJ. 1980; 280: 822-24.
  16. Chollet J.A., Carter G., Meyn L.A., Mermelstein F., Balk J.L. Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis. Menopause. 2009; 16(5): 978-83.
  17. Rymer J., Morris E.P Extracts from «clinical evidence»: menopausal symptoms. BMJ. 2000; 321: 1516-19.
  18. Wu J.M., Matthews C.A., Conover M.M., Pate V., Jonsson Funk M. Lifetime risk of stress urinary incontinence or pelvic organ prolapse surgery. Obstet. Gynecol. 2014; 123(6): 1201-206.
  19. Deffieux X., Letouzey V., Savary D. Prevention of complications related to the use of prosthetic meshes in prolapse surgery: guidelines for clinical practice. Eur. J. Obstet. Gynecol. Reprod. Biol. 2012; 165(2): 170-80.
  20. Rahn D.D., Good M.M., Roshanravan S.M., Shi H., Schaffer J.I., Singh R.J., Word R.A. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. J. Clin. Endocrinol. Metab. 2014; 99(10): 3728-36.
  21. Vaccaro C.M., Mutema G.K., Fellner A.N. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Med. Reconstr. Surg. 2013; 19(1): 34-9.
  22. Rahn D.D., Ward R.M., Sanses T.V. Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. Int. Urogynecol. J. 2015; 26(1): 3-13.
  23. Liapis A., Bakas P., Georgantopoulou C., Creatsas G. The use of oestradiol therapy in postmenopausal women after TVT-O anti-incontinence surgery Maturitas. 2010; 66(1): 101-6.
  24. Karp D.R., Jean-Michel M., Johnston Y. A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Med. Reconstr. Surg. 2012; 18(4): 211-15.
  25. Mikkelsen A.L., Felding C., Clausen H.V. Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A doubleblind, randomized trial. Gynecol. Obstet. Invest. 1995; 40(2): 125-28.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2016

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies